Samuel Menezes

Samuel Menezes

Auto-generated profile, based on publicly available information

Samuel Menezes

Departamento de Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LSLuís Felipe Leite Da Silva
Luís Felipe Leite Da Silva
MNMariana Macambira Noronha
Mariana Macambira Noronha
JMJunior Samuel Alonso de Menezes
Junior Samuel Alonso de Menezes
LCLucas Diniz da Conceição
Lucas Diniz da Conceição
LALuiz Felipe Costa de Almeida
Luiz Felipe Costa de Almeida
TMThais Baccili Cury Megid
Thais Baccili Cury Megid
Epidermal growth factor receptor (EGFR) inhibitors remain a cornerstone in the treatment of metastatic colorectal cancer with RAS and BRAF wild-type cancer. Yet, primary and acquired resistance limit their benefit for many patients. A growing body of evidence reveals that resistance is not random but rather driven by a complex network of molecular alterations that sustain tumor growth independent of EGFR signaling. These include amplification of ERBB2 (HER2) and MET, activation of the PI3K and AKT pathways, EGFR extracellular domain mutations, and rare kinase fusions. The concept of negative hyperselection has emerged as a powerful strategy to refine patient selection by excluding tumors with these resistance drivers. Multiple clinical trials have consistently shown that patients who are hyperselected based on comprehensive molecular profiling achieve significantly higher response rates and improved survival compared to those selected by RAS and BRAF status alone. Liquid biopsy through circulating tumor DNA has further transformed this landscape, offering a noninvasive tool to capture tumor heterogeneity, monitor clonal evolution in real time, and guide rechallenge strategies after resistance emerges. Together, negative hyperselection, ctDNA-guided monitoring, and emerging therapeutics define a precision-oncology framework for identifying, tracking, and overcoming resistance to anti-EGFR therapy in mCRC, moving the field toward more effective and individualized care. Looking ahead, the development of innovative therapeutics such as bispecific antibodies, antibody drug conjugates, and RNA-based therapies promises to further expand in this challenging clinical scenario. These advances move precision oncology in colorectal cancer from concept to clinical reality, reshaping the standard of care through molecular insights.

1 December 2025 in Cancer Research Communications
Verified
Journal Article
Open access
LLLuís Felipe Leite
Luís Felipe Leite
LCLucas Diniz da Conceição
Lucas Diniz da Conceição
ESErick F. Saldanha
Erick F. Saldanha
SMSamuel Menezes
Samuel Menezes
AMAndreia C. De Melo
Andreia C. De Melo
VLVLADMIR Cláudio CORDEIRO DE LIMA
VLADMIR Cláudio CORDEIRO DE LIMA
Cancer is a leading cause of death in Latin America and the Caribbean (LAC), and up-to-date estimates are essential to guide cancer policy. Using GLOBOCAN 2022 data, we analyzed cancer incidence and mortality across 32 LAC countries, calculated age-standardized rates, and assessed early-onset cancer (diagnosed at ages 15–50 years). Mortality-to-incidence ratios were used as a proxy for survival, joinpoint regression estimated annual percent change, and linear regression evaluated correlation between the Human Development Index and cancer indicators. In 2022, LAC recorded 1,551,060 new cancer cases (age-standardized incidence rate, 186.6 per 100,000) and 749,242 deaths (age-standardized mortality rate, 85.2 per 100,000). Prostate and breast cancers were the most common malignancies, whereas lung and breast cancers caused the highest mortality. Mortality declined for prostate cancer [annual percent change, −1.52; 95% confidence interval (CI), −1.80 to −1.24] and male lung cancer (−2.50; 95% CI, −2.68 to −2.33) but increased for female lung (+1.88; 95% CI, 1.71–2.05) and colorectal cancer (+2.48; 95% CI, 2.30–2.67). Human Development Index showed an inverse correlation with mortality-to-incidence ratio (P < 0.001), suggesting improved survival with higher development. Early-onset cancers represented 17% of new cases and 11% of deaths. These findings reveal a growing cancer burden and that persistent disparities in cancer epidemiology persist across LAC, highlighting the urgent need for targeted cancer control strategies and regional cancer control plans. Significance: These findings highlight the urgent need for equity-focused cancer control policies, improved early detection, and expanded access to essential cancer care in the region.

25 April 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
MNMariana Macambira Noronha
Mariana Macambira Noronha
LALuiz Felipe Costa de Almeida
Luiz Felipe Costa de Almeida
ACAnelise Poluboiarinov Cappellaro
Anelise Poluboiarinov Cappellaro
LSLuís Felipe Leite Da Silva
Luís Felipe Leite Da Silva
LCLucas Diniz da Conceição
Lucas Diniz da Conceição
Renata D'Alpino PeixotoRenata D'Alpino Peixoto
Renata D'Alpino Peixoto

30 June 2026 in HPB
Verified
Journal Article
Closed access
LLLuís Felipe Leite
Luís Felipe Leite
MBMarcos Belotto
Marcos Belotto
MSMarcelo de Sá
Marcelo de Sá
SMSamuel Menezes
Samuel Menezes
LALuiz F. de Almeida
Luiz F. de Almeida
José Manuel RamiaJosé Manuel Ramia
José Manuel Ramia

29 August 2025 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
LSLuís Felipe Leite Da Silva
Luís Felipe Leite Da Silva
LALuiz F. Costa de Almeida
Luiz F. Costa de Almeida
SMSamuel Menezes
Samuel Menezes
IRIsabella Romagnoli
Isabella Romagnoli
DSDaniel Dourado Striquer
Daniel Dourado Striquer
MBMarcos Belotto
Marcos Belotto
Background Prophylactic abdominal drainage has been widely used in pancreatic surgery to mitigate postoperative morbidity. Nonetheless, recent evidence suggests that a no-drain policy presents similar results to routine drainage. Therefore, we conducted an updated meta-analysis on this topic to provide up to date clinical recommendations. Methods This systematic review and meta-analysis adhered to PRISMA guidelines and was registered in PROSPERO (CRD42024562683). A comprehensive search of Embase, MEDLINE, CENTRAL, and Web of Science was conducted up to June 2024. Included studies were RCTs comparing prophylactic drainage with no-drain strategies in pancreatic surgery. The ROB-2 tool and GRADE system were used for quality assessment. Results Five RCTs with 1,337 patients (676 with drainage, 661 without) met inclusion criteria. Overall, no significant differences were observed in morbidity, major morbidity, intra-abdominal abscess, wound infection, hemorrhage, or reintervention rates between the two groups (moderate certainty evidence). Notably, the no-drain group had significantly lower 90-day mortality (RR 0.22; 95% CI 0.06–0.75; P < 0.05, moderate certainty evidence). In patients at low risk for POPF, prophylactic drainage was associated with a higher risk of developing POPF (RR 4.32; 95% CI 1.27–14.64; P < 0.05, low certainty evidence). No significant differences were found in patients at moderate or high risk for POPF. Discussion Current evidence indicates that a no-drain policy is associated with comparable safety and efficiency outcomes to prophylactic drainage in pancreatic surgery, with similar mortality and morbidity profiles. In regards to CR-POPF incidence, a no drain policy is a non-inferior approach for PD, while in DP, prophylactic drainage is associated with a higher incidence of fistulas.

9 February 2026 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Open access
SMSamuel Menezes
Samuel Menezes
IBIsabella R. Buonopane
Isabella R. Buonopane
LLLuís Felipe Leite
Luís Felipe Leite
ACAnelise Poluboiarinov Cappellaro
Anelise Poluboiarinov Cappellaro
MBMarcos Belotto
Marcos Belotto
Pancreaticogastrostomy (PG) emerged as a reconstructive option after pancreaticoduodenectomy (PD) due to its reported lower incidence of postoperative pancreatic fistula (POPF), but its superiority over pancreaticojejunostomy (PJ) remains unclear. We provide a narrative review that summarizes its evolution, technical variations, and comparative outcomes versus PJ. A narrative review from a comprehensive literature search was conducted using electronic databases of Medline/PubMed, EMBASE, and the Cochrane Library to identify relevant studies addressing surgical techniques, outcomes, and comparative analyses. PG offers anatomical, physiological advantages, including tension‐free anastomosis and gastric acid inactivation of pancreatic enzymes. Early RCTs showed similar clinically relevant POPF rates. Later trials supported PG for soft glands and small ducts, showing fewer intraperitoneal collections but more hemorrhage. Despite similar short‐term outcomes, long‐term randomized follow‐up shows worse exocrine function after PG than PJ, with higher fecal fat, lower fecal elastase‐1, and greater pancreatic atrophy. PG is an effective reconstruction option after PD, particularly in POPF high‐risk cases. However, it has higher bleeding rates and worse long‐term exocrine function than PJ. Reconstruction should prioritize pancreatic function, favoring PJ for most patients and reserving PG for selected soft, small‐duct, or high‐risk glands based on institutional expertise.